The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Monitoring the MeetingFull Access

Opioids and Cannabis: Myths and Misperceptions

What We Know

Dr. Nora Volkow, Director of the National Institute on Drug Abuse, discussed the opioid epidemic, a public health issue that plagues America. The opioid epidemic was put into the limelight by the media when opioid overdose mortalities surpassed mortalities by motor vehicle accidents in the 1990s, a time in which opioid prescriptions increased drastically. This was fueled by the growing concern of inadequate assessment and treatment of the “fifth vital sign”: patients’ pain. The ubiquity of pain, easy access to narcotic medications, and lack of public awareness about their addictive potential led to widespread misuse. Since 1999, opioid prescriptions have quadrupled, and opioid overdose is on the rise, especially in women ages 45–55 years-old (1).

What Is New

In March 2016, the Centers for Disease Control and Prevention released new opioid prescribing guidelines related to chronic noncancer pain (2). Many states have now mandated the use of prescription monitoring programs before prescribing opioids and other controlled substances in efforts to reduce misuse and make physicians aware of patients’ prescription habits. The biggest impact has come from building awareness of the issue. At the National Prescription Drug Abuse and Heroin Summit in March 2016, President Barack Obama spoke regarding the opioid epidemic. He at once acknowledged the gravity of the problem and rallied America to come together to address the epidemic.

Future Directions

Ongoing research is advancing our understanding of addictive pathways and biochemistry, as well as the identification of biomarkers to recognize which patients are at greater risk for developing addictive disorders (3). The development of opioid formulations that are tamper resistant and the development of pro-drugs might further reduce and deter abuse of prescription opioids (4). Dr. Volkow concluded by challenging physicians everywhere to address pain with more than their prescription pads. She asked that we become advocates for change and build awareness and provide education.

Dr. Patel is a PGY-3 Resident Physician in the Department of Psychiatry, University of Connecticut, Farmington, Conn. Amit Mistry, M.D., is a PGY-2 Resident Physician in the Department of Psychiatry, University of Oklahoma, Oklahoma City, Okla.

The authors thank Dr. Nora Volkow for her continued work in the field of addiction psychiatry.

References

1. Centers for Disease Control and Prevention: National Vital Statistics System, 2016. Atlanta, Centers for Disease Control and Prevention, 2016 Google Scholar

2. Centers for Disease Control and Prevention: CDC Guideline for Prescribing Opioids for Chronic Pain, 2016. Atlanta, Centers for Disease Control and Prevention, 2016. http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm Google Scholar

3. Volkow ND, Koob G: Brain disease model of addiction: why is it so controversial? Lancet Psychiatry, 2015; 2:677–679 CrossrefGoogle Scholar

4. Gudin JA, Nalamachu SR: An overview of prodrug technology and its application for developing abuse-deterrent opioids. Postgrad Med 2016; 128:97–105 CrossrefGoogle Scholar